LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
J. De la Haba Rodriguez(Hospital Universitario Reina Sofía), J. Cortés, Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), I. Blancas López-Barajas(Instituto de Investigación Biosanitaria de Granada), Silvia Patricia Cortez Castedo(Hospital Ruber Internacional), A. López(Hospital de León), Elena López-Miranda(Hospital Universitario Ramón y Cajal), H. Pla Juher(Catalan Institute for Water Research), C.R. Albacar Miro(Hospital Universitari Sant Joan de Reus), J. Ponce(Hospital General Universitario de Alicante Doctor Balmis), V. Carañana Ballerini(Hospital Arnau de Vilanova), L. París Bouzas(Complexo Hospitalario Universitario A Coruña), M. Valero Arbizu(Hospital Quirónsalud Sagrado Corazón), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), Vega Iranzo(Hospital General Universitario De Valencia), A. Garrido(MedSIR (Spain)), Daniel Alcalá-López(MedSIR (Spain)), Leonardo Mina(MedSIR (Spain)), J.J. Garcia Mosquera(Instituto Oncológico Dr. Rosell), A. Llombart Cussac(Hospital Arnau de Vilanova)
Cited by 14Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis